Abstract
Sustained clinical efficacy and safety of adalimumab in patients with moderate to severe psoriatic arthritis (PsA): 2-year results from an open-label extension study
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
